The PROMISE Study

Étudier les personnes à risque plus élevé de myélome multiple et ses conditions précurseurs.

The PROMISE Study identifies people who are at higher risk of developing the blood cancer multiple myeloma. Our team studies their blood samples over time to look for the warning signs of the disease with the aim of finding a way to stop it in its tracks.

OUR STUDY

The PROMISE Study is a collaborative research project that provides free screening for the blood cancer multiple myeloma and its precursor conditions. It is the first study to screen healthy individuals for this disease. Take the first step today to help prevent multiple myeloma before it starts!

OUR STUDY'S GOAL

The PROMISE Study hopes to better understand disease progression to from multiple myeloma’s precursor conditions to overt disease in order to decrease the number of patients progressing to active myeloma.

WHO CAN JOIN?

We’re looking for volunteers who do not have multiple myeloma but may be at a higher risk of developing it in their lifetime. These include:

- Individuals who are over 30 years of age; and

- Individuals who are of African descent; and/or

- Individuals who have a first-degree relative, such as a parent, a sibling, or a child, who has been diagnosed with Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), or any blood cancer; or

- Individuals who have a strong family history of blood cancer (2 or more first- or second-degree relatives with blood cancer) are eligible to participate if they are over 18 years of age.

HOW DO I JOIN?

- Please visit us at promisestudy.org to take our screening survey.

- If you have already visited our webpage and received an email, download the application here and login with the email you received the email at.

Note: The PROMISE study is not for people who have been diagnosed with multiple myeloma, Waldenström macroglobulinemia, any other blood cancer, or one of myeloma’s associated precursor conditions, including multiple gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and smoldering Waldenström macroglobulinemia (SWM).